Novartis Ag Share Price Today
(NASDAQ: NVS)

Name: Novartis Ag Share Price Today (NASDAQ: NVS) - Novartis Ag Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Novartis Ag share price is $104.72 & ₹9,072.94 as on 1 Feb 2025, 2.30 'hrs' IST

$104.72

▲

-0.03

(-0.03%)

Market is closed - opens 8 PM, 03 Feb 2025

View live Novartis Ag share price in Dollar and Rupees. Guide to invest in Novartis Ag stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Novartis Ag, along with analyst recommendations, forecasts, and comprehensive financials.

Novartis Ag share price movements

Today's Low: $104.48
Today's High: $106.72
$104.72
0.23%
Downside
Day's Volatility :2.1%
Upside
1.87%
52 Weeks Low: $92.35
52 Weeks High: $120.92
$104.72
11.81%
Downside
52 Weeks Volatility :23.63%
Upside
13.4%

Novartis Ag (NVS) Returns

Period	Novartis Ag	Sector (Health Care)	Index (Russel 2000)
3 Months	-5.25%	-0.3%	0.0%
6 Months	-4.64%	-2.5%	0.0%
1 Year	0.96%	3.6%	0.0%
3 Years	21.93%	12.0%	-13.7%

Novartis Ag (NVS) Key Statistics

in dollars & INR

Previous Close	$104.75
Open	$106.18
Today's High	$106.72
Today's Low	$104.48
Market Capitalization	$206.6B
Today's Volume	$2.7M
52 Week High	$120.92
52 Week Low	$92.35
Revenue TTM	$49.9B
EBITDA	$21.0B
Earnings Per Share (EPS)	$5.73
PE Ratio	17.96
Dividend Yield	3.63%
Profit Margin	35.25%
Quarterly Earnings Growth YOY	0.85%
Return On Equity TTM	28.79%

How to invest in Novartis Ag Stock (NVS) from India?

It is very easy for Indian residents to invest directly in Novartis Ag from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Novartis Ag stock in both Indian Rupees (INR) and US Dollars (USD). Search for Novartis Ag or NVS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Novartis Ag or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Novartis Ag shares which would translate to 0.008 fractional shares of Novartis Ag as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Novartis Ag, in just a few clicks!

Returns in Novartis Ag (NVS) for Indian investors in Rupees

The Novartis Ag stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Novartis Ag investment value today

Current value as on today

₹1,05,524

Returns

₹5,524

(+5.52%)

Returns from Novartis Ag Stock

₹964 (+0.96%)

Dollar Returns

₹4,559 (+4.56%)

Indian investors sentiment towards Novartis Ag (NVS)

-10.68%

Period: Jan 1, 2025 to Jan 31, 2025. Change in 30 Days versus previous period

Investment in Novartis Ag Shares from India has dropped by -10.68% over the past 30 days, indicating reduced transactional activity.

Period: Jan 1, 2025 to Jan 31, 2025. Change in 30 Days versus previous period

Search interest for Novartis Ag Stock from India on INDmoney has increased by 0% in the last 30 days, reflecting an upward trend in search activity.

Indian Mutual Funds that invest in Novartis Ag Stock (NVS Ticker)

Name	Shares Held	Change in Shares	% of Assets
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	2973	0.00	1.57%

Global Institutional Holdings in Novartis Ag

Dodge & Cox
0.61%
PRIMECAP Management Company
0.60%
Dimensional Fund Advisors, Inc.
0.40%
Morgan Stanley - Brokerage Accounts
0.35%
Loomis, Sayles & Company LP
0.29%
Bank of America Corp
0.25%

Analyst Recommendation on Novartis Ag

Buy

50%Buy

43%Hold

6%Sell

Based on 32 Wall street analysts offering stock ratings for Novartis Ag(by analysts ranked 0 to 5 stars)

Based on 32 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Novartis Ag Stock (NVS)

What analysts predicted

Upside of 7.59%

Target:

$112.67

Current:

$104.72

Insights on Novartis Ag Stock (Ticker Symbol: NVS)

Price Movement
In the last 7 days, NVS stock has moved up by 4.8%
Increasing Revenue
Novartis AG has shown consistent growth in revenue over the past four quarters. Starting at $11.77 billion, the revenue increased to $13.17 billion. This represents an average increase of 3.6% per quarter.
Decreasing Net Profit
Novartis AG has experienced a decline in net profit over the last two quarters. The net profit decreased from $3.24 billion to $3.18 billion, showing an average decrease of 1.8% per quarter.
NVS vs LLY (1 yr)
In the last 1 year, Eli Lilly And Company has given 24.7% return, outperforming this stock by 25.3%
NVS vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 231.6% return, outperforming this stock by 212.8%
Price to Sales
Novartis AG has a Price-to-Sales Ratio of 4.3, which means that investors are willing to pay $4.3 for every $1 of sales the company generates. In comparison, Eli Lilly And Company has a much higher Price-to-Sales Ratio of 17.9, indicating that investors are willing to pay significantly more for each dollar of sales compared to Novartis. This suggests that Novartis may be perceived as a better value in terms of sales performance relative to its market price.

NVS Novartis Ag Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$53.2B	↑ 6.05%
Net Income	$12.6B	↑ 63.72%
Net Profit Margin	23.72%	↑ 8.36%

	FY19	Y/Y Change
Revenue	$48.7B	↓ 8.44%
Net Income	$7.1B	↓ 43.33%
Net Profit Margin	14.68%	↓ 9.04%

	FY20	Y/Y Change
Revenue	$49.9B	↑ 2.51%
Net Income	$8.1B	↑ 12.94%
Net Profit Margin	16.18%	↑ 1.5%

	FY21	Y/Y Change
Revenue	$52.9B	↑ 5.97%
Net Income	$24.0B	↑ 197.58%
Net Profit Margin	45.43%	↑ 29.25%

	FY22	Y/Y Change
Revenue	$51.8B	↓ 1.98%
Net Income	$7.0B	↓ 71.05%
Net Profit Margin	13.42%	↓ 32.01%

	FY23	Y/Y Change
Revenue	$46.7B	↓ 9.97%
Net Income	$14.9B	↑ 113.52%
Net Profit Margin	31.83%	↑ 18.41%

	Q2 FY23	Q/Q Change
Revenue	$13.9B	↑ 5.51%
Net Income	$2.3B	↑ 1.0%
Net Profit Margin	16.62%	↓ 0.74%

	Q3 FY23	Q/Q Change
Revenue	$12.1B	↓ 13.23%
Net Income	$1.8B	↓ 23.96%
Net Profit Margin	14.56%	↓ 2.06%

	Q4 FY23	Q/Q Change
Revenue	$11.8B	↓ 2.61%
Net Income	$8.5B	↑ 381.54%
Net Profit Margin	72.01%	↑ 57.45%

	Q1 FY24	Q/Q Change
Revenue	$11.8B	↑ 0.45%
Net Income	$2.7B	↓ 68.3%
Net Profit Margin	22.72%	↓ 49.29%

	Q2 FY24	Q/Q Change
Revenue	$12.5B	↑ 5.77%
Net Income	$3.2B	↑ 20.76%
Net Profit Margin	25.94%	↑ 3.22%

	Q3 FY24	Q/Q Change
Revenue	$13.2B	↑ 5.27%
Net Income	$3.2B	↓ 1.76%
Net Profit Margin	24.21%	↓ 1.73%

	FY18	Y/Y Change
Profit	$34.8B	↑ 5.46%

	FY19	Y/Y Change
Profit	$34.3B	↓ 1.46%

	FY20	Y/Y Change
Profit	$34.8B	↑ 1.53%

	FY21	Y/Y Change
Profit	$37.0B	↑ 6.42%

	FY22	Y/Y Change
Profit	$36.3B	↓ 1.8%

	FY23	Y/Y Change
Profit	$34.2B	↓ 5.93%

	Q2 FY23	Q/Q Change
Profit	$9.6B	↑ 3.43%

	Q3 FY23	Q/Q Change
Profit	$9.0B	↓ 6.46%

	Q4 FY23	Q/Q Change
Profit	$8.8B	↓ 2.46%

	Q1 FY24	Q/Q Change
Profit	$8.7B	↓ 0.63%

	Q2 FY24	Q/Q Change
Profit	$9.3B	↑ 6.85%

	Q3 FY24	Q/Q Change
Profit	$9.9B	↑ 6.92%

	FY18	Y/Y Change
Operating Cash Flow	$14.3B	↑ 13.08%
Investing Cash Flow	$-5.6B	↑ 79.26%
Financing Cash Flow	$-4.2B	↓ 45.12%

	FY19	Y/Y Change
Operating Cash Flow	$13.6B	↓ 4.53%
Investing Cash Flow	$-2.2B	↓ 60.19%
Financing Cash Flow	$-13.6B	↑ 221.09%

	FY20	Y/Y Change
Operating Cash Flow	$13.7B	↑ 0.18%
Investing Cash Flow	$-13.2B	↑ 492.18%
Financing Cash Flow	$-2.2B	↓ 83.8%

	FY21	Y/Y Change
Operating Cash Flow	$15.1B	↑ 10.41%
Investing Cash Flow	$4.2B	↓ 131.92%
Financing Cash Flow	$-16.3B	↑ 636.59%

	FY22	Y/Y Change
Operating Cash Flow	$14.2B	↓ 5.54%
Investing Cash Flow	$1.5B	↓ 65.11%
Financing Cash Flow	$-20.6B	↑ 26.43%

	FY23	Y/Y Change
Operating Cash Flow	$14.5B	↑ 1.56%
Investing Cash Flow	$5.6B	↑ 281.2%
Financing Cash Flow	$-14.3B	↓ 30.56%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$3.6B	↑ 20.93%
Investing Cash Flow	$-1.1B	↓ 109.91%
Financing Cash Flow	$-3.6B	↓ 60.48%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$5.4B	↑ 50.39%
Investing Cash Flow	$-2.2B	↑ 110.07%
Financing Cash Flow	$-832.0M	↓ 77.12%

	Q4 FY23	Q/Q Change
Operating Cash Flow	$2.5B	↓ 52.64%
Investing Cash Flow	$-1.8B	↓ 20.43%
Financing Cash Flow	$-607.0M	↓ 27.04%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$2.3B	↓ 11.07%
Investing Cash Flow	$-899.0M	↓ 48.92%
Financing Cash Flow	$-5.2B	↑ 750.74%

Novartis Ag Technicals Summary

Sell

Neutral

Buy

Novartis Ag is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Novartis Ag (NVS) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Novartis Ag	7.8%	-4.64%	0.96%	21.93%	11.11%
Eli Lilly And Company	5.8%	6.19%	23.3%	228.2%	483.85%
Johnson & Johnson	6.14%	-5.2%	-2.39%	-11.52%	1.8%
Merck & Co. Inc.	-0.22%	-11.9%	-21.72%	20.66%	13.29%
Novo Nordisk A/s	-3.51%	-32.27%	-25.73%	60.13%	177.07%
Abbvie Inc	-2.11%	-4.72%	4.14%	26.71%	113.43%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Novartis Ag	17.96	17.96	3.08	7.56	0.29	0.11	0.04	21.67
Eli Lilly And Company	89.0	89.0	0.76	12.89	0.65	0.14	0.01	15.83
Johnson & Johnson	26.11	26.11	0.96	10.55	0.21	0.08	0.03	29.14
Merck & Co. Inc.	20.56	20.56	0.07	7.65	0.28	0.11	0.03	17.58
Novo Nordisk A/s	28.29	28.29	1.4	22.15	0.89	0.21	0.02	27.07
Abbvie Inc	61.07	61.07	0.41	10.45	0.56	0.08	0.04	3.41

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Novartis Ag	Buy	$206.6B	11.11%	17.96	35.25%
Eli Lilly And Company	Buy	$740.3B	483.85%	89.0	20.48%
Johnson & Johnson	Buy	$363.9B	1.8%	26.11	16.74%
Merck & Co. Inc.	Buy	$248.6B	13.29%	20.56	19.23%
Novo Nordisk A/s	Buy	$379.5B	177.07%	28.29	35.01%
Abbvie Inc	Buy	$309.7B	113.43%	61.07	9.22%

Novartis Ag Dividend announcements

Novartis Ag Dividends March, 2024
In the quarter ending March,2024. Novartis Ag has declared dividend of $3.78
Read More

About Novartis Ag

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Organization	Novartis Ag
Employees	76057
CEO	Dr. Vasant Narasimhan M.D.
Industry	Health Technology

Management People of Novartis Ag

Name	Title
Dr. Vasant Narasimhan M.D.	Chief Executive Officer
Mr. Harry Kirsch	Chief Financial Officer
Mr. Victor Bulto	President of US
Dr. Patrick Horber M.D.	President of International
Dr. Steffen Lang Ph.D.	President of Operations
Paul Penepent	Head of Group Financial Reporting and Accounting
Ms. Sloan Simpson	Global Head of Investor Relations
Dr. Klaus Moosmayer Ph.D.	Chief Ethics, Risk & Compliance Officer
Ms. Karen L. Hale	Chief Legal Officer
Dr. Robert Kowalski Pharm.D.	Chief People & Organization Officer

Important FAQs about investing in NVS Stock from India :

What is Novartis Ag share price today?

Novartis Ag share price today stands at $104.72, Open: $106.18 ; Previous Close: $104.75 ; High: $106.72 ; Low: $104.48 ; 52 Week High: $120.92 ; 52 Week Low: $92.35.

The stock opens at $106.18, after a previous close of $104.75. The stock reached a daily high of $106.72 and a low of $104.48, with a 52-week high of $120.92 and a 52-week low of $92.35.

Can Indians buy Novartis Ag shares?

Yes, Indians can invest in the Novartis Ag (NVS) from India.

With INDmoney, you can buy Novartis Ag at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Novartis Ag at zero transaction cost.

How can I buy Novartis Ag shares from India?

It is very easy to buy Novartis Ag from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Novartis Ag (NVS) be purchased?

Yes, you can buy fractional shares of Novartis Ag with INDmoney app.

What are the documents required to start investing in Novartis Ag stocks?

To start investing in Novartis Ag, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.